Nivolumab + ipilimumab safe first-line treatment for NSCLC patients with comorbidities Presented ByDr Fabrice Barlesi, Hôpitaux de Marseille, France TrialPhase 4, CHECKMATE-817 ConferenceWCLC 2019 8 November, 2019 21:15
